FIELD: chemistry.
SUBSTANCE: present invention relates to new compound of formula (I) or its pharmaceutically acceptable salt, which have inhibitory effect on EGFR and acts as cell growth inhibitor. In formula: 
m equals 1 or 2; n equals 1 or 2; group R1 is hydrogen atom or C1-C4-alkyl group; and R2, R3 and R4 can be identical or different, and each of them represents hydrogen atom, halogen atom or group presented by formula (a)-CH2-N(R5)(R6)(a), wherein R5 and R6 can be identical or different and each of them represents C1-C4-alkyl group.
EFFECT: compounds can be used for preparing pharmaceutical composition effective for preventing and/or treating cancer, based on inhibiting effect of compound with respect to EGFR.
10 cl, 2 tbl, 25 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL QUINOLINE-SUBSTITUTED COMPOUND | 2014 |
|
RU2689158C2 |
| NEW QUINOLINE-SUBSTITUTED COMPOUND | 2014 |
|
RU2797117C2 |
| PYRIMIDO[5,4-B]INDOLIZINE OR PYRIMIDO[5,4-B]PYRROLIZINE COMPOUND, METHOD FOR PRODUCTION THEREOF AND USE THEREOF | 2017 |
|
RU2721774C1 |
| 7H-PYRROLO[2,3-D]PYRIMIDINE-4-AMINE DERIVATIVE | 2020 |
|
RU2796605C2 |
| EGFR INHIBITOR | 2021 |
|
RU2817044C1 |
| COMBINATION CONTAINING PYRIMIDINE COMPOUND FOR USE IN TREATING TUMOURS | 2021 |
|
RU2827100C1 |
| PYRROLO[2,3-D]PYRIMIDINE COMPOUND OR SALT THEREOF | 2016 |
|
RU2712269C2 |
| ANTITUMOUR EFFECT ENHANCER CONTAINING PYRROLOPYRIMIDINE COMPOUND | 2016 |
|
RU2710380C1 |
| NEW PYRROLOPYRIMIDINE COMPOUND OR ITS SALT, PHARMACEUTICAL COMPOSITION CONTAINING IT, IN PARTICULAR, AGENT FOR PREVENTION AND / OR TREATMENT OF TUMORS AND SO ON, BASED ON INHIBITING INFLUENCE ON NAE | 2015 |
|
RU2658008C2 |
| DERIVATIVES OF PYRROLOPYRIMIDINE USEFUL AS JAK-KINASES INHIBITORS | 2012 |
|
RU2618673C2 |
